Full text is available at the source.
Abstract
A 59-year-old woman with type 2 diabetes developed euglycemic diabetic ketoacidosis (EDKA) after starting dulaglutide following the discontinuation of SGLT-2 inhibitors.
- EDKA is a rare but serious complication associated with type 2 diabetes.
- The patient experienced nausea, vomiting, abdominal pain, and a modestly elevated glucose level.
- Laboratory tests confirmed the diagnosis of EDKA.
- Treatment included intravenous insulin and fluids, leading to recovery.
- Dulaglutide was stopped, and there was no recurrence of EDKA during follow-up.
- This case suggests that GLP-1 receptor agonists may trigger EDKA in certain patients.
Simplified